Additive effects between platelet concentrates and desmopressin in antagonizing the platelet glycoprotein IIb/IIIa inhibitor eptifibatide

Transfusion

Volumn 45, Issue 3, 2005, Pages 420-426

  Reiter, Rosemarie ^a   Jilma Stohlawetz, Petra ^a   Horvath, Michaela ^a   Jilma, Bernd ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DESMOPRESSIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; PLACEBO; THROMBOCYTE CONCENTRATE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; HUMAN; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION;

ADULT; ANTICOAGULANTS; ASPIRIN; BLOOD COMPONENT REMOVAL; BLOOD PLATELETS; CROSS-OVER STUDIES; DEAMINO ARGININE VASOPRESSIN; DRUG SYNERGISM; HEMOSTATICS; HIRUDINS; HUMANS; MALE; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PLATELET TRANSFUSION; RECOMBINANT PROTEINS;

EID: 15244361210     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2005.04021.x     Document Type: Article

References (34)

1. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-9.
2. Coller BS. Anti-GPIIb/IIIa drugs: current strategies and future directions. Thromb Heamost 2001;86:427-43.
3. Jubelirer SJ, Koenig BA, Bates MC. Acute profound thrombocytopenia following C7E3 Fab (abciximab) therapy: case reports, review of the literature and implications for therapy. Am J Hematol 1999;61:205-8.
4. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation 1997;95:809-13.
5. Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa: receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330:956-61.
6. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. The ESPRIT Investigators. Enhanced suppression of the platelet IIb/IIIa receptor with integrilin therapy. Lancet 2000;356:2037-44.
7. Mannucci PM, Aberg M, Nilsson IM, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975;30:81-93.
8. Reiter RA, Mayr F, Blazicek H, et al. Desmopressin antagonize the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood 2003;102:4594-9.
9. Abernethy DR, Pezzullo J, Mascelli MA, et al. Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects. Clin Pharmacol Ther 2002;71:186-95.
10. Stohlawetz P, Hergovich N, Stiegler G, et al. Differential induction of P-selectin expression on platelets by two cell separators during plateletpheresis and the effect of gender on the release of soluble P-selectin. Transfusion 1998;38:24-30.
11. Stohlawetz P, Horvath M, Pernerstorfer T, et al. Effects of nitric oxide on platelet activation during plateletpheresis and in vivo tracking of biotinylated platelets in humans. Transfusion 1999;39:506-14.
12. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001;138:152-63.
13. Jilma-Stohlawetz P, Hergovich N, Homoncik M, et al. Impaired platelet function among platelet donors. Thromb Haemost 2001;86:880-6.
14. Rand ML, Leung R, Packham MA. Platelet function assays. Transfus Apheresis Sci 2003;28:307-17.
15. Harrison P. Progress in the assessment of platelet function. Br J Haematol 2000;111:733-44.
16. Harrison P, Segal H, Furtado C, et al. High incidence of defective high-shear platelet function among platelet donors. Transfusion 2004;44:764-70.
17. Paglieroni TG, Janatpour K, Gosselin R, et al. Platelet function abnormalities in qualified whole-blood donor effects of medication and recent food intake. Vox Sang 2004;86:48-53.
18. Rivas GA, Gonzalez-Rodriguez J. Calcium binding to human platelet integrin GPIIb/IIIa and to its constituent glycoproteins: effects of lipids and temperature. Biochem J 1991;276:35-40.
19. Cierniewski CS, Haas TA, Smith JW, Plow EF. Characterization of cation-binding sequences in the platelet integrin GPIIb-IIIa (alpha IIb beta 3) by terbium luminescence. Biochemistry 1994;33:12238-46.
20. Marguerie GA, Edgington TS, Plow EF. Interaction of fibrinogen with its platelet receptor as part of a multistep reaction in ADP-induced platelet aggregation. J Biol Chem 1980;255:154-61.
21. Johnston GI, Heptinstall S. Identity of saturable calcium-binding sites on blood platelets and their involvement in platelet aggregation. Thromb Haemost 1988;59:54-61.
22. Phillips DR, Teng W, Arfsten A, et al. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997;96:1488-94.
23. Derhaschnig U, Pachinger C, Jilma B. Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: a randomized, placebo-controlled, clinical trial. Am Heart J 2004;147:E17.
24. Marciniak SJ Jr, Jordan RE, Mascelli MA. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban. Thromb Haemost 2001;85:539-43.
25. Harder S, Klinkhardt U, Graff J, et al. In vitro dose-response to different GPIIb/IIIa-antagonists: inter-laboratory comparison of various platelet function tests. Thromb Res 2001;102:39-48.
26. Juergens CP, Yeung AC, Oesterle SN. Routine platelet transfusion in patients undergoing emergency coronary bypass surgery after receiving abciximab. Am J Cardiol 1997;80:74-5.
27. Lemmer JH, Metzdorff MT, Krause AH, et al. Emergency coronary artery bypass graft surgery in abciximab-treated patients. Ann Thorac Surg 2000;69:90-5.
28. Alvarez JM. Emergency coronary bypass grafting for failed percutaneous coronary artery stenting: increased costs and platelet transfusion requirements after the use of abciximab. J Thorac Cardiovasc Surg 1998;115:472-3.
29. Kottke-Marchant K, Powers JB, Brooks L, Kundu S, Christie DJ. The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100). Clin Appl Thromb Hemost 1999;5:122-30.
30. Lepantalo A, Beer JH, Siljander P, Syrjala M, Lassila R. Variability in platelet responses to collagen - comparison between whole blood perfusions, traditional platelet function tests and PFA-100. Thromb Res 2001;103:123-33.
31. Storey RF, Wilcox RG, Heptinstall S. Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists. Circulation 1998;98:1616-21.
32. Strauss RG. Economy of platelet transfusions from a hospital perspective: pricing predicates practice. Transfusion 2001;41:1617-24.
33. Mascelli MA, Lance ET, Damaraju L, et al. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998;97:1680-8.
34. Galan AM, Bozzo J, Hernandez MR, et al. Infusible platelet membranes improve hemostasis in thrombocytopenic blood: experimental studies under flow conditions. Transfusion 2000;40:1074-80.